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Introduction: We have assessed the utility of autologous mesenchymal stem cell (MSC) peripheral vein infusion as
a possible therapeutic modality for patients with end-stage liver diseases.
Methods: Forty patients with post-hepatitis C virus (HCV) end-stage liver disease were randomized into two
groups: Group 1 (GI): 20 patients who received granulocyte colony-stimulating factor (G-CSF) for 5 days followed
by autologous MSCs peripheral-vein infusion and group 2 (GII): 20 patients who received regular liver-supportive
treatment only (control group).
Results: In MSC-infused patients (GI), 54% showed near normalization of liver enzymes and improvement in
liver synthetic function. Significant changes were reported in albumin (P = 0.000), bilirubin (P = 0.002), increased
international normalized ratio (INR) (P = 0.017), prothrombin concentration (P = 0.029) and alanine transaminase
(ALT) levels (P = 0.029), with stabilization of clinical and biochemical status in 13% of cases. None of the patients
in GII showed any significant improvement. Hepatic fibrosis was assessed in GI by detection of procollagen IIIC
peptide level (PIIICP) and procollagen III N peptide level (PIIINP). The pretreatment values of s-PIIICP and s-PIIINP
were 9.4 ± 4.2 and 440 ± 189, respectively, with a decrease to 8.1 ± 2.6 and 388 ± 102, respectively, 3 months after
MSC therapy. However, the difference was statistically nonsignificant (P = 0.7). A significant correlation coefficient
was reported after 3 months between the s-PIIINP and prothrombin concentration (P = −0.5) and between
s-PIIICP and ascites (P = 0.550).
Conclusions: First, autologous MSC infusion into a peripheral vein is as effective as the previously reported
intrahepatic infusion. Second, MSCs have a supportive role in the treatment of end-stage liver disease, with
satisfactory tolerability and beneficial effects on liver synthetic functions and hepatic fibrosis. Third, IV infusion of
MSCs after G-CSF mobilization improves s-albumin within the first 2 weeks and prothrombin concentration and
alanine Taransaminase after 1 month. According to the data from this current study and those previously
reported by our group, we recommend further studies on patients’ infusion with pure CD133 and CD34 followed
by IV infusion of in vitro-differentiated MSCs within 1 week and another infusion after 3 months.
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Cirrhosis is the end stage of chronic liver injury caused
by viral hepatitis or alcohol intake. In Egypt, which has a
very high incidence of hepatitis C virus (HCV) infection,
most malignant neoplasms of the liver arise on top of
chronically damaged livers, typically a cirrhotic liver [1].
Although liver transplantation is considered the most
effective treatment for those patients, it is critically lim-
ited by the shortage of available donors. Until now, ef-
fective treatments capable of reversing cirrhosis have not
been developed. However, in the last few years, increas-
ing evidence suggests that adult cells have greater differ-
entiation plasticity than previously thought, with bone
marrow (BM) turning into skeletal muscles [2] brain [3],
or liver [4].
Several previous studies demonstrate that hematopoietic
BM stem cells transplantation improves the residual liver
function in cirrhosis patients. These results were consid-
ered promising and encouraging [5,6]. The bone marrow is
a reservoir of various stem cells, including hematopoietic
stem cells (HSCs) and mesenchymal stem cells (MSCs).
Because the bone marrow-derived MSCs were found to
have differentiative plasticity, great interest has occurred in
their potential therapeutic application [7]. The MSCs are
capable of mesodermal and neuroectodermal differenti-
ation, they have the potential of endodermal differentiation,
and their differentiation into functional hepatocyte-like
cells has also been demonstrated. Nevertheless, studies on
MSCs as a potential treatment for chronic liver diseases
are not as advanced as those in other fields [8]. We previ-
ously showed that a CD34+ and CD133+ stem cells infu-
sion can be used as supportive treatment for end-stage
liver disease in the Egyptian population with satisfac-
tory tolerability [9,10]. In the current study, we sought
to assess the possibility of using MSCs followed by G-CSF
mobilization intravenous infusion as a therapeutic mo-
dality in patients with end-stage liver diseases in com-




This prospective study included 40 patients with post-HCV
end-stage liver disease who were eligible for treatment
intervention. Patients were recruited from the Hepatology
outpatient clinics at Kasr El Aini hospitals and the National
Cancer Institute, Cairo University, Cairo, Egypt, during
the period from June 2010 to October 2011. The enrolled
patients were randomized into one of two groups; Group 1
(GI, the tested group) included 20 patients who received
granulocyte colony-stimulating factor (G-CSF) (Neupogen;/
Roche) for 5 days, followed by autologous mesenchymal
stem cell (MSC) infusion, and Group 2 (GII, the control
group) included 20 patients who received regular livertreatment. All patients had abnormal s-albumin, bilirubin,
and INR values, Childs-Pugh scores B and C, a World
Health Organization (WHO) performance status of 3 or
higher, were unable to receive a liver transplantation be-
cause of organ shortage and the high cost of liver trans-
plantation in Egypt, and all have the ability to give an
informed consent to the procedure. All patients (MSCs
transplantation and the control group) were followed up
for at least 26 weeks or until they died.
Inclusion criteria
Patients included in the study fulfilled the following cri-
teria: male or female, aged from 20 to 60 years with evi-
dence of chronic liver insufficiency (decreased s-albumin
and/or increased bilirubin and/or increased INR), un-
likely to receive a liver transplant, have a World Health
Organization (WHO) performance score of less than 2
and are able to give a written consent. None of the pa-
tients has received interferon or other therapy within
6 months before cell transplantation or during the
follow-up period. All patients were negative for hepatic
fibrosis and for portal-tract thickening that is character-
istic of schistosomiasis.
Exclusion criteria
Patients were excluded from the study if younger than 20
or more than 60 years old; pregnant or lactating; had re-
cent and/or recurrent upper gastrointestinal bleeding or
spontaneous bacterial peritonitis (SBP) within 1 month
before the procedure or HCC, an evidence of human im-
munodeficiency virus or other life-threatening infection;
unable to give a written consent; have a history of hyper-
sensitivity to G-CSF, or included in any other clinical trial
within the previous month.
Patients in both groups were comparable for baseline
characteristics including age and sex, etiology of liver
disease, and MELD score. Clinical evaluation was done
for all patients, including a detailed medical history and
complete clinical examination with special emphasis on
the presence of evidence of liver cell failure (for example,
ascites, jaundice, lower-limb edema, bleeding tendency, or
signs of encephalopathy, in addition to the WHO per-
formance score. Laboratory investigations were done for
all patients including liver biochemical profile [s-bilirubin,
s-albumin, prothrombin time and concentration, INR,
alanine transaminase (ALT) and aspartate transaminase
(AST)], blood urea, serum creatinine levels, blood sugar
(fasting and 2 hours after food), complete blood count
(hemoglobin, white blood cell count, platelet count),
coagulation profile (prothrombin time, INR, APPT), α-
fetoprotein and hepatitis serologic profile (HBsAg, HBcAb,
HCV-Ab, and HCV-RNA by quantitative polymerase chain
reaction and HIV). Abdominal ultrasound scanning
was done for both groups by using a Hitachi 515 real-
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MSCs transplantation), and MELD score was calculated
to assess the degree of hepatic decompensation for
every patient.
Ethics
The ethical committees of Kaser El-Aini School of Medi-
cine and the National Cancer Institute, Cairo University,
approved the study protocol, which was in accordance
with the Declaration of Helsinki, and a written informed
consent was obtained from each patient before enroll-
ment in the study.
Treatment protocols
A. Treatment protocol for GI (MSCs transplantation):
Patients in GI received IV MSCs infusion according
to the following protocol:
 G-CSF injection: All patients received a daily
subcutaneous injection of 300 μg of G-CSF
(Neupogen; Roche Pharmaceutical) for 5 days to
increase the number of the BM-derived stem cells
(BMSCs) and hematopoietic stem cells, days 1 to 5.
 BM stem cell aspiration: Patient’s skin was
cleaned with 70% alcohol at the iliac crest, which
is the usual site for puncture in adults. The skin,
subcutaneous tissues, and periosteum overlying
the selected site for puncture were infiltrated
with xylocaine local anesthesia, and serial
punctures from multiple sites were performed.
With a boring movement, needles (Salah and
Klima) were passed perpendicularly into the
cavity of the ileum at a point just posterior to the
anterior superior iliac spine or 2 cm posterior
and 2 cm inferior to the anterior superior iliac
spine to aspirate 300 ml of the BM. The collected
BM products were transferred to the stem cell
laboratory for immunomagnetic purification of
CD34+ and CD133+ stem cell population by
using the positive cell-selection kit (MACS
System Miltenyi Biotec, GmbH, Germany) [11].
The isolated CD34+ and CD133+ cells were
washed with phosphate-buffered saline (pH 7.4)
supplemented with 0.5% bovine serum albumin
and 5 mM EDTA, and centrifuged at 1,500 r/min
for 10 minutes at 4°C. Cells were counted,
adjusted to 0.5 × 108, centrifuged, and
resuspended in 100 ml physiological saline.
 MSC differentiation: The cells were cultured in
DMEM/HamF12/mesenchymal stem cell media
(25%/25%/50%) containing 10% bovine serum
albumin (BSA; Invitrogen), 1% penicillin/
streptomycin (Invitrogen), 1 ng/ml G-CSF,
hepatocyte growth factor (HGF; 5 ng/ml Sigma,H1404), and liver extract (10 ng/ml, Sigma;
G7387). Cells were incubated for 5 to 7 days
at 37°C in 5% CO2 and examined with
phase-contrast microscopy for morphologic
changes characteristic of MSCs differentiation.
A critical point for successful differentiation into
MSCs, in the current study, was the relation
between the number of cultured cells, the surface
area of the tissue-culture flasks used, and the
amount of the tissue-culture media.
 Characterization of cultured cells: Cells were
periodically examined with phase-contrast
microscopy for morphologic changes indicating
transdifferentiation into MSCs. Aliquots of
cultured cells were also obtained for
immunophenotypy characterized with flow
cytometry by using surface MSCs markers
(CD44-FITC, CD90-PerCP, CD29-FITC, and
CD105y versus CD45-PE). Cells were considered
MSCs if they were negative for CD45-PE
and positive for CD44-FITC, CD90-PerCP,
CD29-FITC, and CD105y (either one or all of them)
 Injection of transdifferentiated MSCs: On day 7
after BM aspiration, patients were admitted to
hospital while fasting for intravenous infusion
with approximately 1 × 106/kg body weight of the
expanded MSCs. Figure 1 illustrates the working
steps as a simple work-flow chart.
B. Treatment protocol for GII (regular liver
treatment): Patients in GII received their usual,
regular supportive liver treatment
Follow-up of patients after MSCs infusion
All patients in both groups were followed up every hour for
24 hours, then weekly for the first month, and monthly for
6 months. During the follow-up, the patients were observed
for clinical improvement through assessment of the degree
of fluid retention (ascites and LL edema), performance sta-
tus and score, biochemical assessment including s-bilirubin
and albumin, prothrombin time and concentration, INR,
ALT and AST, blood urea, and s- creatinine levels, blood
sugar (fasting and 2 hours after a meal), complete blood
analysis, together with assessment of Child-Pugh score pro-
gression. Procollagen III was evaluated by using human
procollagen C-terminal propeptide ELISA (ng/ml) and hu-
man procollagen N-terminal propeptide ELISA.
Statistical analysis
All patients’ data were tabulated and processed with SPSS
(Statistical Package for Science and Society) version 12.0 for
Windows XP. The descriptive statistics were presented as
mean ± SD for quantitative variables, whereas qualitative
data were expressed as frequency (number) and percentage.
Figure 1 Work flow chart.
Table 1 The results of baseline laboratory and clinical





Mean ± SD Mean ± SD
Age (years, mean ± SD) 50.27 ± 6.05 50.9 ± 7.23
Sex
Male 17 (85%) 16 (80%)
Female 3 (15%) 4 (20%)
Residence
Urban 7 (35%) 8 (40%)
Rural 13 (65%) 12 (60%)
Clinical features
Hemoglobin (g/dl) 12.22 ± 2.24 9.77 ± 2.13
TLC (1,000/cmm) 5.81 ± 3.22 5.73 ± 2.24
Platelets (1,000/cmm) 105.95 ± 47.17 91.75 ± 33.67
Total bilirubin (N, 0.1 to 1 mg/dl) 1.88 ± 1.05 2.51 ± 0.94
Serum albumin (N, 3.4 to 5.2 g/dl) 2.59 ± 0.28 2.62 ± 0.37
PC 55.34% ± 9.06% 52.85 ± 10.16%
INR (N, 1) 1.53 ± 0.19 1.66 ± 0.33
ALT folds 1.35 ± 0.87 0.9 ± 0.52
AST folds 2.29 ± 1.51 1.81 ± 0.84
Serum creatinine (0.7-1.2 mg/dl) 1.1 ± 0.29 1.06 ± 033
Encephalopathy 1 (5%) 2 (10%)
Ascites and lower-limb edema 15 (75%) 15 (75%)
Bleeding tendency 10 (50%) 10 (50%)
Hematemesis 0 (0) 2 (10%)
Spleen size
Average size 5 (25%) 5 (25%)
Mild splenomegaly 11 (55%) 12 (60%)
Moderate splenomegaly 4 (20%) 3 (15%)
Splenectomy 0 0
Ascites
Absent 9 (45%) 5 (25%)
Mild 2 (10%) 2 (10%)
Moderate 7 (35%) 9 (45%)
Massive 2 (10%) 4 (20%)
None of these parameters showed significant differences between the two groups.
ALT, alanine aminotransferase; AST,aspartate aminotransferase; INR, International
Normalized Ratio; PC, prothrombin concentration; TLC, total leukocyte count.
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χ2 test, Fischer Exact test, or McNemar test when appropri-
ate for qualitative data. Independent-sample t test and
paired-sample t test were used for normally distributed
quantitative variables. The nonparametric Mann-Whitney
test and Wilcoxon signed ranks test were used for abnor-
mally distributed quantitative variables. Percentage changes
in prognostic variables were calculated and compared by
using the Mann-Whitney test. P values lower than 0.05were considered statistically significant. Linear regression
analysis was used to determine the degree of improvement
of the clinical features in relation to response to treatment.
Results
The baseline laboratory and clinical features of patients in
both studied groups are illustrated in Table 1. As for MSCs-
injected patients (GI), the baseline mean of s-albumin
started to increase 2 weeks after SC infusion (P = 0.001),
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(P = 0.000), and 6 months (P = 0.000). All liver-function
tests, adjusted for age and sex, improved significantly
including bilirubin (P = 0.002), ALT (P = 0.029), AST
(P = 0.156) INR (P = 0.017), and PC (P = 0.029).
No statistically significant difference was found be-
tween the studied groups regarding the renal functions
at baseline and all through the study. During 6 months
of follow-up of the MSCs-treated patients (with ultra-
sonography, Doppler, and s-AFP), no focal lesions or
portal vein thrombosis was detected. No mortality was
recorded within 6 months of treatment, although five
patients died in the control group during this period.
Table 2 illustrates the biochemical changes in both stud-
ied groups during the follow-up period.
At the end of the study, four patients (20%) showed
improvement of their Child-Pugh grade compared with
the baseline (Figure 2).
Ascites
In this study, ascites was assessed by abdominal ultrasound
examination; ascites only in the pelvis and/or hepato-renalTable 2 Changes in the studied groups (mean ± SD)
Pretreatment 2 weeks
Bilirubin
Treated 1.88 ± 1.05 1.92 ± 1.22
Control 2.51 ± 0.94 2.87 ± 1.5
P value 0.4 0.025
Albumin
Treated 2.59 ± 0.28 3.03 ± 0.44
Control 2.62 ± 0.37 2.63 ± 0.27
P value 0.77 0.001
PC (%)
Treated 55.34 ± 9.06 61.15 ± 15.99
Control 52.85 ± 10.16 53.65 ± 11.01
P value 0.41 0.92
INR
Treated 1.53 ± 0.19 1.47 ± 0.29
Control 1.66 ± 0.33 1.62 ± 0.39
P value 0.12 0.2
ASTfold
Treated 2.29 ± 1.51 2.03 ± 0.79
Control 1.81 ± 0.84 1.68 ± 0.65
P value 0.46 0.14
ALT fold
Treated 1.35 ± 0.87 1.17 ± 0.71
Control 0.9 ± 0.52 0.87 ± 0.41
P value 0.55 0.13
ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International Nangle is considered mild; If it reaches the mid-abdomen, it
is moderate, and more than that is massive ascites. At the
beginning of the study, 10% of the MSCs-treated patients
(GI) had massive ascites, 35% had moderate ascites, 10%
had mild ascites, and 45% had no ascites compared with
20% with massive ascites, 45% with moderate ascites, 10%
with mild ascites, and 25% with no ascites in the control
group (GII). Two weeks after MSCs infusion, 60% of pa-
tients had no ascites, 15% had mild ascites, 20% had mod-
erate ascites, and 5% had massive ascites.
One month later, 65% of the patients had no ascites,
10% had mild ascites, 15% had moderate ascites, and
10% had massive ascites compared with 60% with no as-
cites, 5% with mild ascites, 15% with moderate ascites,
and 20% with massive ascites after 3 months.
After 6 months of follow-up, 65% of the patients had
no ascites, 5% had mild ascites, 10% had moderate asci-
tes, and 20% had massive ascites.
In the control group, 25% of the patients had no ascites,
10% had mild ascites, 45% had moderate ascites, and 20%
had massive ascites after 2 weeks compared with 15% with
no ascites, 15% with mild ascites, 55% with moderateFirst month Third month Sixth month
1.89 ± 1.36 1.82 ± 1.3 2.06 ± 1.26
3.3 ± 2.14 4.02 ± 3.29 4.24 ± 2.48
0.006 0.001 0.002
3.05 ± 0.41 2.99 ± 0.26 3.06 ± 0.36
2.63 ± 0.14 2.63 ± 0.3 2.43 ± 0.36
0.000 0.000 0.000
62.89 ± 18.2 59.45 ± 15.23 57.59 ± 14.68
49.35 ± 10.35 50.45 ± 11.42 45.03 ± 10.92
0.007 0.041 0.029
1.44 ± 0.28 1.47 ± 0.23 1.52 ± 0.36
1.76 ± 0.4 1.73 ± 0.4 1.84 ± 0.39
0.007 0.31 0.017
1.83 ± 1.13 1.97 ± 1.09 2.14 ± 0.88
1.75 ± 0.71 1.66 ± 0.73 1.64 ± 0.69
0.85 0.48 0.156
1.1 ± 0.58 1.06 ± 0.64 1.27 ± 0.3
0.81 ± 0.46 0.81 ± 0.54 1.09 ± 1.47
0.172 0.093 0.029
ormalized Ratio; PC, prothrombin concentration; TLC, total leukocyte count.
Figure 2 Child-Pugh scores in the study population (A) and control group (B).
Figure 3 Scattered plot distribution of PIIINP concentration in treated group before transplant, after 1 month, after 3 months, and
after 6 months.
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Table 3 Correlation coefficient between PIIINP and the
following parameters
Pretreatment 1 month 3 months 6 months
Albumin 0.06 −0.04 0.3 0.2
INR(a) −0.5 −0.1 0.4 0.4
PC(b) 0.5 0.1 −0.5* −0.3
Ascites 0.03 0.2 0.2 0.04
*There is significant correlation coefficient between PIIINP and Prothrombin
concentration after 3 months.
a: INR, International Normalized Ratio; b: PC, prothrombin concentration.
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follow-up. Three months later, 10% of the patients had no
ascites, 15% had mild ascites, 30% had moderate ascites,
and 45% had massive ascites. After 6 months, 13.3% of the
patients had mild ascites, 40% had moderate ascites, and
46.7% had massive ascites (P = 0.07; P = 0.001).
Hepatic encephalopathy
At the beginning, 95% of the patients in the MSCs-treated
group were free of encephalopathy attacks compared with
75% in the control group (P = 0.18). After 2 weeks, 90%
of the MSCs-treated patients were free of attacks of
encephalopathy compared with 75% in the control group
(P = 0.4), and after one month, 95% of the patients in
MSCs treated group had no attacks compared to 70% in
the control group (P = 0.09). After 3 months of follow-up,
85% of the patients in MSCs-treated group had no attacks
of encephalopathy compared with 60% in the control
group (P = 0.77), and after 6 months, 75% of patients in
the MSCs-treated group had no attacks compared with
46.7% in the control group (P = 0.08). No statistically sig-
nificant difference was noted between both studied groups
during the whole follow-up period.
Hematemesis
At the beginning of the study, 100% of patients had no
history of hematemesis in the MSCs-treated groupFigure 4 Correlation coefficient between PIIINP and prothrombin concompared with 90% in the control group (P = 0.48) com-
pared with 100% and 95%, respectively, in both studied
groups after 2 weeks and 1 month of follow-up (P = 1.0).
After treatment, no further attacks of hematemesis oc-
curred in the MSCs-treated group 3 or 6 months after
MSCs infusion, whereas 15% and 26.7% of the patients
in the control group had attacks of hematemesis at 3
and 6 months, respectively, because of bleeding esopha-
geal varices. The difference between the two groups was
statistically significant after 6 months (P =0.026) but not
after 3 months (P = 0.23).
Regarding the mortality rate, no mortality was reported
in the MSCs treated group while five patients in the con-
trol group died (all were child C), three of them due to
hepatic encephalopathy and two due to un-controlled at-
tacks of haematemesis.
Fibrosis biomarkers
The mean pretreatment serum baseline level of the
PIIINP was 440 ± 189, then 468 ± 212, 388 ± 102, then
408 ± 156 after 1 month of treatment, 3 months, and at
the end of the study, respectively. The difference was
statistically insignificant (P = 0.4) (Figure 3). Conversely,
the difference in s-PIIINP level and PC (prothrombin
concentration) before and 3 months after treatment with
IV-MSCs infusion was statistically significant (P < 0.05)
(Table 3, Figure 4).
The mean pretreatment serum baseline level of the
PIIICP was 9.4 ± 4.25; then it was 9.4 ± 4.2 after 1 month
of treatment, 8.1 ± 2.6 after 3 months, and 8.7 ± 3.1 at
the end of the study. The difference was statistically in-
significant (P = 0.7) (Figure 5). However, A significant
correlation was reported between s-PIIICP and ascites
after 3 months of treatment with IV-MSCs (P = 0.550*)
(Table 4, Figure 6).
Health quality-of-life assessment showed a statistically
significant improvement in the MSCs-treated patients
started in the second week after treatment until the endcentration.
Figure 5 Scattered plot distribution of PIIICP concentration in the treated group before transplant, 1 month, 3 months and 6 months.
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atic coma and hematemesis were detected in all treated
patients compared with the control group.
Discussion
Cirrhosis represents the final pathologic outcome for the
majority of chronic liver disease cases. Until now, liver
transplantation has been considered the only curative
treatment for decompensated cirrhosis [12]. However, this
procedure is limited by technical difficulties, high cost,
and also by a lack of donors [13]. In many recent studies,
some done by our team, have shown that BMSCs trans-
plantation can restore liver mass and function, alleviate fi-
brosis, and correct inherited liver diseases [6,14]. In the
current study, we evaluated the efficacy of peripheral vein
infusion MSCs followed G-CSF mobilization as a treat-
ment for patients with end-stage liver disease, and we con-
firmed our previous data regarding the supportive role of
SC transplantation in patients with end-stage liver disease.
The SC therapy is affected by many variables, includ-
ing the type and number of transplanted cells, the cul-
ture media used, and the growth factors which are
added to the culture media to support growth and differ-
entiation of cells, the administration route, and the post-
treatment care. In the current study, the treated group
received 300 μg G-CSF daily for 5 days. The G-CSF isTable 4 Correlation coefficient between PIIICP and the
following parameters
Pretreatment 1 month 3 months 6 months
Albumin 0.3 −0.07 0.08 0.3
INR(a) −0.2 −0.1 0.14 0.3
PC(b) 0.15 0.16 −0.3 −0.3
Ascites 0.12 0.3 0.550* 0.1
*There is significant correlation coefficient between PIIICP and ascites
after 3 months.
a: INR, International Normalized Ratio; b: PC, prothrombin concentration.effective in mobilizing bone marrow cells into the per-
ipheral blood and then homing into the liver [12]. Stud-
ies in rats demonstrate that G-CSF induces liver repair
by increasing the BM-derived liver repopulation, and ac-
tivating the endogenous oval cells, which express G-CSF
receptor (G-CSFR) [15]. The G-CSF mobilized periph-
eral bone marrow cells (PBMCs) secrete chemokines
might enhance the transplanted PBMCs, which are lo-
cated in the injured liver and cytokines that enhance the
proliferation of the transplanted cells or hepatic stem
cells, and they also induce apoptosis of liver stellate cells
[15,16]. It is now clear that the modulation of hepatic
stellate cells’ activity is one of the main causes of liver
cirrhosis, and this is through collagen deposition, vaso-
constriction, and regulation of sinusoidal structure,
which are the results of the changes in stellate cells’ acti-
vation. Consequently, reversing these changes in hepatic
stellate cells activity, induction of apoptosis, inhibition of
matrix formation, as well as degradation of established
matrix could be the strategy for inhibition of liver cirrhosis
progression [17-20].Figure 6 Correlation coefficient between PIIICP and ascites.
Figure 7 Performance-score difference after 2 weeks, 1, 3, and 6 months in treated group.
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represent an excellent extrahepatic source for hepato-
cytes to induce liver regeneration. As previously shown,
the MSCs play an important role in the molecular sig-
naling during early development of the liver [21,22].
They express a number of growth-factor receptors, such
as fibroblast growth factor receptor (FGFRs), and the re-
ceptor for HGF (c-met) [23,24], and they also induce al-
terations in the dendritic cells (DCs) cytokines secretion
[25,26]. As a result, they upregulate the antiinflamma-
tory Th2 cytokines (IL-3, 5, 10, and 14) and downregu-
late the proinflammatory Th1 cytokines (IL-1α and,
IFNγ, and TNFα) [26,27].
It was also shown that the MSCs may act directly as
an anti-collagen formation agent rather than an immune
regulator. MSCs can correct the liver functions through
downregulation of the collagen matrix formation. The
results of the current study confirm previously published
data regarding MSCs functions, since we reported a de-
crease in serum levels of the hepatic fibrosis markers,
PIIICP and PIIINP, in the MSCs-infused patients. Similar
findings were also reported by Terai et al. [5]. Taken to-
gether, this indicates that downregulation of collagen
matrix formation reflects an increase in serum albumin
level and reduces ascites. All of these factors make us
think of the MSCs as the perfect choice for liver stem
cell therapy, as they could help in different developmen-
tal stages of the liver and restoring liver functions.
In the current study, five patients (25%) showed an im-
provement of the grade of ascites, as assessed by abdom-
inal ultrasound, compared with the baseline. This is in
agreement with the results of Terai et al. [5], Gordon et al.
[28], and Pai et al. [14] by using autologous mesenchymal
bone marrow transplantation and Salama et al. [9] by using
autologous CD34+ and CD133+ stem cell infusion.
Our data regarding the improvements in liver functions
and ascites also support the utility of MSCs. We foundthat, in more than 75% of the MSCs-infused patients s-
albumin started to improve 2 weeks after the procedure
and until the end of the study without albumin infusion
compared with the control group. The difference between
the two groups was statistically significant difference,
which is in agreement with our previous studies [9,10] as
well as with those of Gordon et al. [28] and Terai et al. [5]
using autologous bone marrow cell infusion (ABMI). In
addition, we have observed improvement in the ALT,
AST, and S-albumin levels, which is in agreement with
our previous data using autologous CD34+ and CD133+
stem cell infusion [9], as well as Gordon et al. [28] and
Lyra et al. [29].
As for the hepatic functional reserve, our data showed
improvement in the Child-Pugh score as well as in the
performance score (PS), which led to improvement in
the quality of life in the MSCs-treated group, which
started 2 weeks after the procedure until the end of the
study, which is in consistent with those of with our pre-
vious study using autologous CD34+ and CD133+ stem
cell infusion [9] as well as Terai et al. [5], Pai et al. [14],
and Gordon et al. [28].
No agreement exists regarding the cell number of thera-
peutic stem cells to be infused. In previous studies, au-
thors had used different doses: 1 × 105 embryonic stem
cells [30] and 31.73 × 106 autologous BMSCs for LC pa-
tients [31]. In an earlier study, we found that a high dose
(1 × 1011) was not suitable for the patients [10], as it could
lead to portal hypertension and lung edema; therefore, in
the current study, we injected all patients with 1 × 107
cells/kg of body weight. Although this dose is higher than
any previously injected doses, it was tolerable and proved
to be very safe and without any clinical complication on
follow-up.
Similarly, one of the aims of this study was to assess
the efficiency of the peripheral-vein infusion as a route
of administration of the MSCs after G-CSF mobilization.
Figure 8 This diagram illustrates our assumption of concomitant mode of action of both GCSF priming followed by MSC
transplantation for regeneration of liver cells in end-stage liver disease.
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http://stemcellres.com/content/5/3/70It also proved to be safe and superior to other previously
used routes. The peripheral intravenous infusion is an
easy and convenient way of stem cells delivery, with
less-invasive and less-traumatic effects, and it does not
need advanced medical equipment. However, as a sys-
temic administration, concerns exist of the possible side
effects, such as fever and immunoreaction. Our study
provided that the peripheral vein infusion is as evidenced
by the low incidence of complications encountered after
6 months’ follow-up of the treated group by ultrasonog-
raphy, Doppler, and serum α-fetoprotein. No focal lesionsor portal vein thrombosis were detected after the pro-
cedure. This is in agreement with Mohamadnejad M
et al. [30], who previously showed that MSCs can differ-
entiate into hepatocyte and nonhepatocyte cells and
that MSCs infusion through a peripheral vein can pre-
vent liver cell failure and lead to regression of liver fi-
brosis. When we compared the peripheral vein infusion
to the intrahepatic infusion, which we used in our previ-
ous studies [9,10]; we did find any significant differences
either in the overall clinical outcome or in the incidence
of complications, between the two used procedures. We
Salama et al. Stem Cell Research & Therapy 2014, 5:70 Page 11 of 12
http://stemcellres.com/content/5/3/70have also observed in this study that the serum albumin
has been improved faster than that in our previous
studies [9,10].
Conclusion
We conclude that (a) a combination of G-CSF with MSCs
will greatly improve the outcome of stem cell-treated pa-
tients with end-stage liver disease. (b) The intravenous
route is a safe and easy way for MSCs infusion in end-
stage liver disease and with fewer complications compared
with intraarterial infusion route, and (c) MSCs may act
directly through preventing collagen formation, as evi-
denced by their ability to reduce the hepatic fibrosis
markers. Taken together, our data provides evidence that
MSCs followed GCSF mobilization is excellent for liver
stem cell therapy to retain liver mass and restore liver
functions (Figure 8).
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